Literature DB >> 22516382

Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy.

Pretesh R Patel1, Sua Yoo, Gloria Broadwater, Lawrence B Marks, Edward F Miles, Thomas A D'Amico, David Harpole, Chris R Kelsey.   

Abstract

PURPOSE: To assess the impact of increasing experience with intensity-modulated radiation therapy (IMRT) after extrapleural pneumonectomy (EPP) for malignant pleural mesothelioma (MPM). METHODS AND MATERIALS: The records of all patients who received IMRT following EPP at Duke University Medical Center between 2005 and 2010 were reviewed. Target volumes included the preoperative extent of the pleural space, chest wall incisions, involved nodal stations, and a boost to close/positive surgical margins if applicable. Patients were typically treated with 9-11 beams with gantry angles, collimator rotations, and beam apertures manually fixed to avoid the contalateral lung and to optimize target coverage. Toxicity was graded retrospectively using National Cancer Institute common toxicity criteria version 4.0. Target coverage and contralateral lung irradiation were evaluated over time by using linear regression. Local control, disease-free survival, and overall survival rates were estimated using the Kaplan-Meier method.
RESULTS: Thirty patients received IMRT following EPP; 21 patients also received systemic chemotherapy. Median follow-up was 15 months. The median dose prescribed to the entire ipsilateral hemithorax was 45 Gy (range, 40-50.4 Gy) with a boost of 8-25 Gy in 9 patients. Median survival was 23.2 months. Two-year local control, disease-free survival, and overall survival rates were 47%, 34%, and 50%, respectively. Increasing experience planning MPM cases was associated with improved coverage of planning target volumes (P=.04). Similarly, mean lung dose (P<.01) and lung V5 (volume receiving 5 Gy or more; P<.01) values decreased with increasing experience. Lung toxicity developed after IMRT in 4 (13%) patients at a median of 2.2 months after RT (three grade 3-4 and one grade 5). Lung toxicity developed in 4 of the initial 15 patients vs none of the last 15 patients treated.
CONCLUSIONS: With increasing experience, target volume coverage improved and dose to the contralateral lung decreased. Rates of pulmonary toxicity were relatively low. However, both local and distant control rates remained suboptimal.
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22516382     DOI: 10.1016/j.ijrobp.2011.11.057

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  21 in total

1.  Extra-pleural pneumonectomy in the era of image-guided intensity-modulated radiotherapy.

Authors:  Marco Trovo; Davide Franceschini; Carlo Furlan; Francesca Pietrobon; Stefano Vagge; Eleonora Farina; Alberto Revelant; Luca Visani; Virginia Maragna; Giuseppe Parisi; Vieri Scotti
Journal:  Radiol Med       Date:  2019-04-08       Impact factor: 3.469

Review 2.  Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma.

Authors:  Licun Wu; Marc de Perrot
Journal:  Transl Lung Cancer Res       Date:  2017-06

3.  Novel radiation therapy approaches in malignant pleural mesothelioma.

Authors:  Andreas Rimner; Kenneth E Rosenzweig
Journal:  Ann Cardiothorac Surg       Date:  2012-11

Review 4.  Recent advances in radiotherapy for thoracic tumours.

Authors:  Michael Fay; Christopher M Poole; Gary Pratt
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 5.  Adjuvant, neoadjuvant, and definitive radiation therapy for malignant pleural mesothelioma.

Authors:  Gwendolyn Cramer; Charles B Simone; Theresa M Busch; Keith A Cengel
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

6.  Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.

Authors:  Fauzia Shaikh; Marjorie G Zauderer; Donata von Reibnitz; Abraham J Wu; Ellen D Yorke; Amanda Foster; Weiji Shi; Zhigang Zhang; Prasad S Adusumilli; Kenneth E Rosenzweig; Lee M Krug; Valerie W Rusch; Andreas Rimner
Journal:  J Thorac Oncol       Date:  2017-03-21       Impact factor: 15.609

7.  Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.

Authors:  Andreas Rimner; Marjorie G Zauderer; Daniel R Gomez; Prasad S Adusumilli; Preeti K Parhar; Abraham J Wu; Kaitlin M Woo; Ronglai Shen; Michelle S Ginsberg; Ellen D Yorke; David C Rice; Anne S Tsao; Kenneth E Rosenzweig; Valerie W Rusch; Lee M Krug
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

Review 8.  Malignant pleural mesothelioma: adjuvant therapy with radiation therapy.

Authors:  Kenneth E Rosenzweig
Journal:  Ann Transl Med       Date:  2017-06

Review 9.  Proton beam therapy for malignant pleural mesothelioma.

Authors:  Shahed N Badiyan; Jason K Molitoris; Mingyao Zhu; Erica Glass; Tejan Diwanji; Charles B Simone
Journal:  Transl Lung Cancer Res       Date:  2018-04

Review 10.  Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health.

Authors:  Volker Neumann; Stefan Löseke; Dennis Nowak; Felix J F Herth; Andrea Tannapfel
Journal:  Dtsch Arztebl Int       Date:  2013-05-03       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.